PIK3CA
2 drugsPhosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
Predictive biomarker for patient selection in 2 indications
Understanding PIK3CA
What it means: PIK3CA mutations activate the PI3K pathway, promoting cell growth and survival. Found in ~40% of HR+ breast cancers.
Why it matters: PI3K inhibitor alpelisib (combined with fulvestrant) approved for PIK3CA-mutated HR+/HER2- breast cancer.
Testing: Tested via NGS or PCR on tumor tissue or ctDNA. FDA-approved companion diagnostic available.
2
Approved Drugs
2
Indications
1
Companies
Search PIK3CA Clinical Trials
Search recruiting trials on ClinicalTrials.gov